Loading...
Loading...
India's verapamil imports from BANGLADESH total $2 across 2 shipments from 1 foreign suppliers. ESKAYEF PHARMACEUTICALS LIMITED leads with $2 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include CLIANTHA RESEARCH LIMITED. This corridor reflects India's pharmaceutical import demand for verapamil โ a concentrated sourcing relationship with select suppliers from BANGLADESH.

ESKAYEF PHARMACEUTICALS LIMITED is the leading Verapamil supplier from BANGLADESH to India, with import value of $2 across 2 shipments. The top 5 suppliers โ ESKAYEF PHARMACEUTICALS LIMITED โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | ESKAYEF PHARMACEUTICALS LIMITED | $2 | 2 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | CLIANTHA RESEARCH LIMITED | $2 | 2 | 100.0% |
BANGLADESH โ India trade corridor intelligence
The Bangladesh to India trade corridor is currently stable, with no significant port congestion reported at major entry points like Jawaharlal Nehru Port Trust (JNPT), Chennai, or Mundra. Freight rates remain competitive, and the exchange rate between the Indian Rupee (INR) and Bangladeshi Taka is favorable for trade. No major disruptions have been reported in the 2025โ2026 period.
The Indian government's Production Linked Incentive (PLI) scheme aims to boost domestic manufacturing, potentially reducing reliance on imports. However, for specialized formulations like Verapamil, domestic production may not meet demand, necessitating continued imports from countries like Bangladesh.
India and Bangladesh share a robust trade relationship, with ongoing negotiations to enhance bilateral trade, including the pharmaceutical sector. Mutual recognition of Good Manufacturing Practices (GMP) has been established, facilitating smoother trade and regulatory processes. These agreements aim to streamline the import process and ensure the quality of pharmaceutical products.
The landed cost for importing Verapamil formulations from Bangladesh to India includes the following components:
A detailed per-unit estimate requires specific FOB prices and freight details, which are not provided in the available data.
CDSCO registration, import licensing, and quality testing requirements
Importing finished pharmaceutical formulations containing Verapamil into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) mandates that both the drug and the manufacturing site be registered. For new drugs, approval under Rule 122E is necessary before registration and import. Applications for registration and import should be submitted to the Drugs Controller General (I) at CDSCO. The registration process involves submitting Form 40 or 41, along with the required documentation, and may take several months, depending on the completeness of the application and the nature of the drug. Specific requirements for Verapamil formulations under HS Code 30049072 include detailed product information, manufacturing details, and compliance with Indian pharmacopoeia standards.
Imported Verapamil formulations must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is mandatory, with each batch accompanied by a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to ICH Zone IV guidelines, is required to demonstrate the product's shelf-life under Indian climatic conditions. Port inspections by customs drug inspectors are conducted to verify the authenticity and quality of the imported drugs. Failure to meet these standards can result in rejection of the batch and potential penalties.
Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of imports. Bilateral agreements between India and Bangladesh have facilitated smoother trade, including mutual recognition of Good Manufacturing Practices (GMP), which may streamline the import process for Bangladeshi manufacturers.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 10%
India imports finished Verapamil formulations to meet the demand for specific dosage forms and branded products not available domestically. The market size for Verapamil in India is substantial, driven by its use in treating cardiovascular conditions. Domestic manufacturers may lack the capacity to produce certain formulations, leading to reliance on imports to fulfill market needs.
The Basic Customs Duty (BCD) for Verapamil formulations under HS Code 30049072 is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable on the CIF value. Additionally, a Social Welfare Surcharge (SWS) of 10% on BCD is levied. This results in a total landed duty of approximately 23.536% of the CIF value. There are no specific exemptions or concessional rates for imports from Bangladesh under this HS code.
India sources Verapamil formulations from Bangladesh due to competitive advantages such as cost-effective manufacturing and compliance with international quality standards. Bangladesh's share in India's Verapamil import market is significant, offering specialized formulations and dosage forms that may not be produced domestically. Other suppliers include China, Germany, and the United States, but Bangladesh's proximity and trade agreements enhance its competitive position.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Verapamil formulations from Bangladesh due to the availability of specialized dosage forms and branded products not produced domestically. Bangladesh's compliance with international quality standards and cost-effective manufacturing processes make it an attractive source for these formulations.
Compared to other origins like China, the European Union, and the United States, Bangladesh offers competitive pricing and quality. Its proximity to India and established trade agreements further enhance its appeal as a sourcing destination.
Potential risks include reliance on a single source, currency fluctuations, regulatory changes, quality control issues, and shipping disruptions. While no significant shortages have been reported, importers should monitor these factors to mitigate potential impacts.
Import license checklist, document requirements, quality testing, and compliance
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Verapamil suppliers from BANGLADESH to India include ESKAYEF PHARMACEUTICALS LIMITED. The leading supplier is ESKAYEF PHARMACEUTICALS LIMITED with import value of $2 USD across 2 shipments. India imported Verapamil worth $2 USD from BANGLADESH in total across 2 shipments.
India imported Verapamil worth $2 USD from BANGLADESH across 2 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Verapamil sourced from BANGLADESH include CLIANTHA RESEARCH LIMITED. The largest buyer is CLIANTHA RESEARCH LIMITED with $2 in imports across 2 shipments.
The total value of Verapamil imports from BANGLADESH to India is $2 USD, across 2 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists